Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Lersch, C; Schmelz, R; Eckel, F; Erdmann, J; Mayr, M; Schulte-Frohlinde, E; Quasthoff, S; Grosskreutz, J; Adelsberger, H.
Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
Clin Colorectal Cancer. 2002; 2(1): 54-58.
Doi: 10.3816/CCC.2002.n.011
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Quasthoff Stefan
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Oxaliplatin plays a key role in the treatment of advanced colorectal cancer. The dose-limiting side effect of this platinum analogue is neurotoxicity. Significant efforts have been undertaken in an attempt to prevent and/or circumvent the development of neurotoxicity. Sodium channel inactivation kinetics on rat sensory sural nerve preparations are altered after exposure to oxaliplatin. Carbamazepine antagonizes this effect in vitro. Results from preliminary clinical studies indicate that the sodium channel blockers carbamazepine and gabapentin may be effective in preventing neurotoxicity. The role of amifostine is not yet clear. Randomized clinical studies are necessary to confirm the potential benefit of carbamazepine and other sodium channel blockers in preventing and/or overcoming the development of oxaliplatin-induced neurotoxicity.
- Find related publications in this database (using NLM MeSH Indexing)
- Animals -
- Antineoplastic Agents - adverse effects
- Carbamazepine - therapeutic use
- Colorectal Neoplasms - drug therapy
- Humans - drug therapy
- Neurotoxicity Syndromes - prevention and control
- Organoplatinum Compounds - adverse effects
- Peripheral Nervous System Diseases - chemically induced
- Rats - chemically induced
- Sodium Channel Blockers - therapeutic use